AstraZeneca strikes $2.4bn deal for radiotherapy biotech Fusion
Acquisition gives pharmaceutical group mid-stage asset to challenge Novartis in new form of cancer care
Acquisition gives pharmaceutical group mid-stage asset to challenge Novartis in new form of cancer care